Ivonescimab Biosimilar – Anti-VEGF & PD1 mAb – Research Grade

What is Ivonescimab?

Ivonescimab (AK112) is an antibody developed to target both PD-1 and VEGF pathways, two key mechanisms involved in immune regulation and angiogenesis. It is widely studied in immuno-oncology research for its ability to modulate tumor immune responses while impacting vascular development.

Mechanism of Action

This ivonescimab antibody is used in research to explore combined inhibition of PD-1-mediated immune checkpoint signaling and VEGF-driven angiogenesis. Such dual pathway targeting is of particular interest in studies of tumor progression and therapeutic response.

Applications

• Immuno-oncology research
• PD-1 immune checkpoint studies
• Angiogenesis and VEGF pathway analysis
• Combination therapy research
• Preclinical evaluation of antibody-based approaches

Key Features

• Targets PD-1 and VEGF-related pathways
• Suitable for advanced research applications
• Consistent performance and reproducibility
• Research-grade biosimilar format

About PD-1 and VEGF targeting

PD-1 is a key immune checkpoint receptor involved in regulating T-cell activity, while VEGF plays a central role in angiogenesis. Targeting both pathways is widely investigated in oncology research to better understand tumor immune evasion and vascular development.

Ivonescimab Antibody Price and Cost

The price of ivonescimab antibody depends on the required format, quantity, and research specifications. ProteoGenix provides high-quality biosimilars at competitive cost, ensuring accessibility for research applications.

For detailed pricing or bulk orders, you can request a quote directly from our team.

This product is available for fast delivery within the United States.

Need a tailored antibody solution?

If your research requires specific antibody formats or optimized targeting strategies, custom antibody development solutions can support advanced experimental needs.